Comparative scRNA-seq Reveals Liver Metastasis-Specific Targets in a Patient with Small Intestinal Neuroendocrine Cancer

Genomic analysis of a patients' tumor is the cornerstone of precision oncology, but it doesn't address whether metastases should be treated differently. Here we tested whether comparative scRNA-seq of a primary small intestinal neuroendocrine tumor to a matched liver metastasis could guide treatment of a patients' metastatic disease. Following surgery, the patient was put on maintenance treatment with a somatostatin analog. However, the scRNA-seq analysis revealed that the neuroendocrine epithelial cells in the liver metastasis were less differentiated and expressed relatively little SSTR2, the predominant somatostatin receptor. There were also differences in the tumor microenvironments. RNA expression of vascular endothelial growth factors was higher in the primary tumor cells, reflected by an increased number of endothelial cells. Interestingly, vascular expression of the major VEGF receptors was considerably higher in the liver metastasis, indicating that the metastatic vasculature may be primed for expansion and susceptible to treatment with angiogenesis inhibitors. The patient eventually progressed on sandostatin and although consideration was given to adding an angiogenesis inhibitor to her regimen, her disease progression involved non-liver metastases which had not been characterized. Although in this specific case comparative scRNA-seq did not alter treatment, its potential to help guide therapy of metastatic disease was clearly demonstrated.